Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270956 · ClinicalTrials.gov registry record · Phase 2
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
A Phase 2 study, sponsored by Prokidney.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03270956: Completed Phase 2 study, sponsored by Prokidney.
NCT03270956 is a Phase 2 study that has completed, run by Prokidney. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03270956, a Phase 2 study, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
Primary Outcome
Percentage of subjects with procedures and/or product related adverse events by System Organ Class and Preferred Term
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
What the finished NCT03270956 record still lists
NCT03270956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT03270956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03270956 about?
NCT03270956 is a clinical study titled "A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease". The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
What is the current status of trial NCT03270956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-04-25. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT03270956?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03270956?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03270956's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI